PE20090146A1 - Composicion inmunogenica contra el virus influenza - Google Patents
Composicion inmunogenica contra el virus influenzaInfo
- Publication number
- PE20090146A1 PE20090146A1 PE2008000650A PE2008000650A PE20090146A1 PE 20090146 A1 PE20090146 A1 PE 20090146A1 PE 2008000650 A PE2008000650 A PE 2008000650A PE 2008000650 A PE2008000650 A PE 2008000650A PE 20090146 A1 PE20090146 A1 PE 20090146A1
- Authority
- PE
- Peru
- Prior art keywords
- per dose
- tlr
- influenza virus
- refers
- amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16251—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
SE REFIERE A COMPOSICIONES INMUNOGENICAS CONTRA LA GRIPE, QUE COMPRENDEN: A)UN ANTIGENO DEL VIRUS INFLUENZA QUE CONSISTE EN 15ug O MENOS DE HA POR DOSIS; B)UN COADYUVANTE DE EMULSION DE ACEITE EN AGUA, COMPUESTO POR: a)UN ACEITE METABOLIZABLE, TAL COMO ESCUALENO EN 0,5-10mg A 9-10mg POR DOSIS; b)UN AGENTE EMULSIVO, TAL COMO MONOOLEATO DE POLIOXIETILENSORBITANO, TRIOLEATO DE SORBITANO O MEZCLA DE AMBOS EN CANTIDAD DE 0,1-5mg A 4-5mg POR DOSIS; c)UN TOCOL, EN CANTIDAD DE 0,5-12 A 10-11mg POR DOSIS; UN ESTEROL EN CANTIDAD DE 0,025-2,5mg A 0,125-0,25mg POR DOSIS; O AMBOS; d)UN LIGANDO TLR, TAL COMO TLR-1, TLR-2, TLR-3, ENTRE OTROS, O COMBINACIONES DE LOS MISMOS; e)UNA SAPONINA, TAL COMO QS21 EN 5-60ug A 40-50ug POR DOSIS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION. DICHA COMPOSICION PUEDE SER MONO O MULTIVALENTE DE VIRUS COMPLETO, DIVIDIDO O VIROSOMA DE UNO O MAS ANTIGENOS PURIFICADOS ELEGIDOS DE: HA, NA, M1, M2; COMPRENDIENDO ANTIGENOS SELECCIONADOS DE LAS CEPAS: H1N1, H3N2, B/yamagata, B/victoria, H5N1, ENTRE OTRAS, Y SE ADMINISTRA EN DOSIS MENORES A 1,2mL
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0707697A GB0707697D0 (en) | 2007-04-20 | 2007-04-20 | Vaccine |
GB0711357A GB0711357D0 (en) | 2007-06-12 | 2007-06-12 | Vaccine |
GB0712062A GB0712062D0 (en) | 2007-06-21 | 2007-06-21 | Vaccine |
PCT/EP2007/060743 WO2008043774A1 (en) | 2006-10-12 | 2007-10-10 | Vaccine comprising an oil in water emulsion adjuvant |
GB0724651A GB0724651D0 (en) | 2007-12-18 | 2007-12-18 | Vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20090146A1 true PE20090146A1 (es) | 2009-03-23 |
Family
ID=39766893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008000650A PE20090146A1 (es) | 2007-04-20 | 2008-04-15 | Composicion inmunogenica contra el virus influenza |
Country Status (20)
Country | Link |
---|---|
US (4) | US9452209B2 (es) |
EP (2) | EP2136837B1 (es) |
JP (1) | JP2010524883A (es) |
KR (1) | KR101188382B1 (es) |
CN (2) | CN101678096A (es) |
AR (1) | AR066405A1 (es) |
AT (1) | ATE537841T1 (es) |
AU (1) | AU2008240761B2 (es) |
CA (1) | CA2683075C (es) |
CO (1) | CO6251369A2 (es) |
CR (1) | CR11122A (es) |
DO (1) | DOP2009000239A (es) |
EA (1) | EA024250B1 (es) |
ES (1) | ES2377761T3 (es) |
IL (1) | IL200859A (es) |
MA (1) | MA31381B1 (es) |
PE (1) | PE20090146A1 (es) |
TW (1) | TW200908994A (es) |
WO (1) | WO2008128939A1 (es) |
ZA (1) | ZA200906753B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
PT1154790E (pt) * | 1999-02-26 | 2005-03-31 | Chiron Srl | Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg |
GB9923176D0 (en) * | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
US20100221284A1 (en) * | 2001-05-30 | 2010-09-02 | Saech-Sisches Serumwerk Dresden | Novel vaccine composition |
DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
AU2006226543B2 (en) * | 2005-03-23 | 2011-10-06 | Glaxosmithkline Biologicals S.A. | Use of an influenza virus an oil-in-water emulsion adjuvant to induce CD4 T-cell and/or improved B-memory cell response |
US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
HUE051122T2 (hu) | 2005-11-04 | 2021-03-01 | Seqirus Uk Ltd | Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák |
US20090304742A1 (en) * | 2005-11-04 | 2009-12-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines with reduced amount of emulsion adjuvant |
EP2043682B1 (en) | 2006-07-17 | 2014-04-02 | GlaxoSmithKline Biologicals S.A. | Influenza vaccine |
BRPI0717219B8 (pt) * | 2006-10-12 | 2021-05-25 | Glaxosmithkline Biologicals Sa | composição imunogênica, e, uso de uma composição imunogênica |
PE20090146A1 (es) * | 2007-04-20 | 2009-03-23 | Glaxosmithkline Biolog Sa | Composicion inmunogenica contra el virus influenza |
AU2008281384C1 (en) * | 2007-08-02 | 2012-08-16 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope influenza vaccines |
US8506966B2 (en) | 2008-02-22 | 2013-08-13 | Novartis Ag | Adjuvanted influenza vaccines for pediatric use |
KR101701198B1 (ko) | 2008-06-19 | 2017-02-01 | 배리에이션 바이오테크놀로지스 아이엔씨. | 인플루엔자를 치료하기 위한 조성물 및 방법 |
CA2737455A1 (en) | 2008-09-18 | 2010-03-25 | Novartis Ag | Vaccine adjuvant combinations |
KR20110132373A (ko) | 2009-02-10 | 2011-12-07 | 노파르티스 아게 | 유행병-연관 주에 대한 인플루엔자 백신 요법 |
AU2015203072B2 (en) * | 2009-02-10 | 2017-05-25 | Seqirus UK Limited | Influenza vaccine regimens for pandemic-associated strains |
CA2751379C (en) * | 2009-02-10 | 2018-06-12 | Novartis Ag | Influenza vaccines with reduced amounts of squalene |
USH2283H1 (en) | 2009-04-27 | 2013-09-03 | Novartis Ag | Vaccines for protecting against influenza |
US20110097418A1 (en) * | 2009-05-29 | 2011-04-28 | Variation Biotechnologies, Inc. | Compositions and methods for treating influenza |
EP2491392A1 (en) * | 2009-10-21 | 2012-08-29 | De Staat Der Nederlanden, Vert. Door De Minister Van VWS | Methods for diagnosis of immune responses against viruses |
GB0919117D0 (en) | 2009-10-30 | 2009-12-16 | Glaxosmithkline Biolog Sa | Process |
WO2012020326A1 (en) | 2010-03-18 | 2012-02-16 | Novartis Ag | Adjuvanted vaccines for serogroup b meningococcus |
WO2011130652A2 (en) * | 2010-04-15 | 2011-10-20 | George Baer | Compositions and methods for vaccinating humans and animals against enveloped viruses |
KR102471356B1 (ko) * | 2010-06-01 | 2022-11-28 | 노파르티스 아게 | 동결건조하지 않는 인플루엔자 백신 항원의 농축 |
GB201009273D0 (en) * | 2010-06-03 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel vaccine |
EP2585106A1 (en) | 2010-06-25 | 2013-05-01 | Novartis AG | Combinations of meningococcal factor h binding proteins |
ES2612511T3 (es) * | 2011-01-27 | 2017-05-17 | Glaxosmithkline Biologicals Sa | Nanoemulsiones de adyuvante con inhibidores de cristalización |
US9303070B2 (en) * | 2011-02-22 | 2016-04-05 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
US10183069B2 (en) | 2011-03-21 | 2019-01-22 | Altimmune Inc. | Rapid and prolonged immunologic-therapeutic |
AU2012324398A1 (en) * | 2011-10-20 | 2014-05-01 | Seqirus UK Limited | Adjuvanted influenza B virus vaccines for pediatric priming |
RU2599496C2 (ru) * | 2012-03-06 | 2016-10-10 | Круселл Холланд Б.В. | Улучшенная вакцинация против гриппа |
GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
JP6719388B2 (ja) * | 2014-12-25 | 2020-07-08 | テルモ株式会社 | 皮内投与インフルエンザワクチン組成物 |
CA3045563C (en) * | 2016-12-23 | 2022-05-03 | Intervet International B.V. | Combination vaccine for swine |
US20200222550A1 (en) | 2017-01-31 | 2020-07-16 | Merck Sharp & Dohme Corp. | Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f |
MX2019009580A (es) * | 2017-02-13 | 2020-01-30 | Boehringer Ingelheim Animal Health Usa Inc | Aplicador de liquidos para suministrar vacunas. |
WO2020160080A1 (en) * | 2019-01-30 | 2020-08-06 | Glaxosmithkline Llc | Oil/surfactant mixtures for self-emulsification |
EP3953457A4 (en) * | 2019-04-06 | 2023-01-11 | Altimmune Inc | BROAD AND LONG-TERM FLU VACCINE |
RU2740751C1 (ru) * | 2019-08-28 | 2021-01-20 | Общество с ограниченной ответственностью "Развитие БиоТехнологий" | Способ получения тетравалентной субъединичной противогриппозной вакцины |
CN113827715A (zh) * | 2020-06-23 | 2021-12-24 | 普莱柯生物工程股份有限公司 | 一种抗h7亚型和h5亚型禽流感病毒的疫苗组合物、及其制备方法和应用 |
JP2023548866A (ja) | 2020-10-29 | 2023-11-21 | インダストリアル ポリマーズ アンド ケミカルズ, インコーポレイテッド | 病原体監視及び不活性化のエアフィルター |
WO2023059857A1 (en) * | 2021-10-08 | 2023-04-13 | Sanofi Pasteur Inc. | Multivalent influenza vaccines |
KR20240033309A (ko) * | 2022-09-05 | 2024-03-12 | 주식회사 차백신연구소 | 에멀전 제형의 면역증강제 조성물 및 이의 제조 방법 |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3238190A (en) | 1963-10-23 | 1966-03-01 | Madaus & Co K G Fa Dr | Aescin recovery |
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
DD155875A1 (de) | 1980-12-31 | 1982-07-14 | Willy Nordheim | Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes |
US4454119A (en) | 1981-06-29 | 1984-06-12 | Mitsubishi Chemical Industries Limited | Therapeutic agents |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
FI69639C (fi) | 1982-07-02 | 1986-03-10 | Orion Yhtymae Oy | Preparat foer anvaendning vid klamydia-diagnostik |
DD211444A3 (de) | 1982-08-19 | 1984-07-11 | Saechsisches Serumwerk | Verfahren zur herstellung von influenza-impfstoffen |
GB8300467D0 (en) | 1983-01-08 | 1983-02-09 | Wellcome Found | Equine influenza |
FI861417A0 (fi) | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
DD300833A7 (de) | 1985-10-28 | 1992-08-13 | Saechsische Landesgewerbefoerd | Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
AU614755B2 (en) | 1987-06-05 | 1991-09-12 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Autocrine motility factors in cancer diagnosis and management |
EP1088830A3 (en) | 1987-06-22 | 2004-04-07 | Medeva Holdings B.V. | Hepatitis b surface antigen particles |
DE3734306A1 (de) | 1987-10-10 | 1989-04-27 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung fuer fliessfaehige medien |
US5376369A (en) | 1987-11-03 | 1994-12-27 | Syntex (U.S.A.) Inc. | Vaccine adjuvant |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
GB8819209D0 (en) | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
GB8821049D0 (en) | 1988-09-08 | 1988-10-05 | Health Lab Service Board | Method & composition for treatment & prevention of viral infections |
US4999403A (en) | 1988-10-28 | 1991-03-12 | Exxon Chemical Patents Inc. | Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions |
ES2068989T3 (es) | 1989-02-04 | 1995-05-01 | Akzo Nobel Nv | Tocoles como adyuvante en vacunas. |
HU212924B (en) * | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
ATE159031T1 (de) | 1989-07-25 | 1997-10-15 | Smithkline Biolog | Antigene sowie verfahren zu deren herstellung |
DE4005528C2 (de) | 1990-02-22 | 1998-01-15 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung für Medien |
US5969109A (en) | 1990-02-28 | 1999-10-19 | Bona; Constantin | Chimeric antibodies comprising antigen binding sites and B and T cell epitopes |
US5149531A (en) | 1990-06-27 | 1992-09-22 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza |
US5030115A (en) | 1990-07-23 | 1991-07-09 | Molex Incorporated | Tired socket assembly with integral ground shield |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
GB9105992D0 (en) | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
DE69228698T2 (de) | 1991-11-16 | 1999-09-16 | Smithkline Beecham Biolog | HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG |
MA22842A1 (fr) | 1992-03-27 | 1993-10-01 | Smithkline Beecham Biolog | Procede de preparation de compositions de vaccin. |
AU6141094A (en) | 1993-02-19 | 1994-09-14 | Smithkline Beecham Biologicals (Sa) | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
AU685443B2 (en) | 1993-03-23 | 1998-01-22 | Smithkline Beecham Biologicals (Sa) | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
US5762939A (en) * | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
SK281944B6 (sk) | 1993-11-17 | 2001-09-11 | Laboratoires Om S. A. | Beta(1->6)glukozamínové disacharidy, spôsob ich prípravy, farmaceutický prostriedok, ktorý ich obsahuje, a ich použitie |
GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
JP3836874B2 (ja) | 1994-02-24 | 2006-10-25 | ノババックス インコーポレイテッド | 免疫アジュバントとして少ラメラ脂質小胞を含むワクチン |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
ES2267100T5 (es) | 1994-07-15 | 2011-04-08 | The University Of Iowa Research Foundation | Oligonucleótidos inmunomoduladores. |
US5629052A (en) | 1995-02-15 | 1997-05-13 | The Procter & Gamble Company | Method of applying a curable resin to a substrate for use in papermaking |
WO1996026277A1 (en) | 1995-02-24 | 1996-08-29 | Cantab Pharmaceuticals Research Limited | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
US20030133944A1 (en) | 2001-04-05 | 2003-07-17 | Smithkline Beecham Biologicals S.A. | Vaccine composition against malaria |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
WO1998050567A1 (en) | 1997-05-02 | 1998-11-12 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
ES2298316T3 (es) | 1997-09-05 | 2008-05-16 | Glaxosmithkline Biologicals S.A. | Emulsiones de aceite en agua que contienen saponinas. |
US7459524B1 (en) | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
CA2330610A1 (en) | 1998-05-07 | 1999-11-11 | Corixa Corporation | Adjuvant composition and methods for its use |
WO1999064301A1 (fr) | 1998-06-08 | 1999-12-16 | Sca Emballage France | Emballage a remise a plat rapide |
CZ302062B6 (cs) | 1998-06-30 | 2010-09-22 | Om Pharma | Derivát acyldipeptidu, zpusob jeho prípravy, meziprodukty pro jeho prípravu a farmaceutický prostredek, který ho obsahuje |
AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
AT407958B (de) | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
WO2000050006A2 (en) | 1999-02-26 | 2000-08-31 | Chiron Corporation | Microemulsions with adsorbed macromoelecules and microparticles |
GB9923176D0 (en) * | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
AU1581400A (en) | 1999-12-22 | 2001-07-03 | Om Pharma | Acyl pseudopeptides bearing a functionalised auxiliary spacer |
MXPA02007413A (es) | 2000-01-31 | 2004-07-30 | Smithkline Beecham Biolog | Vacuna para la inmunizacion profilactica o terapeutica contra el vih. |
GB0025577D0 (en) | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
EP1201250A1 (en) | 2000-10-25 | 2002-05-02 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Immunogenic compositions comprising liver stage malarial antigens |
EP2269639B1 (en) | 2001-02-23 | 2018-11-28 | GlaxoSmithKline Biologicals s.a. | Influenza vaccine formulations for intradermal delivery |
ES2314042T3 (es) | 2001-04-17 | 2009-03-16 | Dainippon Sumitomo Pharma Co., Ltd. | Derivados nuevos de adenina. |
TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
DK1719511T3 (da) | 2001-11-16 | 2009-04-14 | Coley Pharm Group Inc | N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf |
US6861410B1 (en) | 2002-03-21 | 2005-03-01 | Chiron Corporation | Immunological adjuvant compositions |
US20040074760A1 (en) * | 2002-10-17 | 2004-04-22 | Carnegie Mellon University | Production of biofuels |
EP1594536B1 (en) | 2003-01-30 | 2009-03-25 | Novartis Vaccines and Diagnostics, Inc. | Adjuvanted influenza vaccine |
WO2004071459A2 (en) | 2003-02-13 | 2004-08-26 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor 8 |
CN1522691A (zh) * | 2003-09-05 | 2004-08-25 | 韦怀新 | 核酸、蛋白多肽及疫苗乳剂的制备方法 |
US20080254065A1 (en) | 2004-03-09 | 2008-10-16 | Chiron Corporation | Influenza Virus Vaccines |
US20090028903A1 (en) * | 2005-03-23 | 2009-01-29 | Glaxosmithkline Biologicals, S.A. | Novel use |
AU2006226543B2 (en) | 2005-03-23 | 2011-10-06 | Glaxosmithkline Biologicals S.A. | Use of an influenza virus an oil-in-water emulsion adjuvant to induce CD4 T-cell and/or improved B-memory cell response |
AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
HUE051122T2 (hu) | 2005-11-04 | 2021-03-01 | Seqirus Uk Ltd | Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák |
US20090304742A1 (en) | 2005-11-04 | 2009-12-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines with reduced amount of emulsion adjuvant |
FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
EP2043682B1 (en) | 2006-07-17 | 2014-04-02 | GlaxoSmithKline Biologicals S.A. | Influenza vaccine |
US20080014217A1 (en) * | 2006-07-17 | 2008-01-17 | Emmanuel Jules Hanon | Influenza vaccine |
DK2043682T3 (da) * | 2006-07-17 | 2014-06-02 | Glaxosmithkline Biolog Sa | Influenzavaccine |
BRPI0717219B8 (pt) * | 2006-10-12 | 2021-05-25 | Glaxosmithkline Biologicals Sa | composição imunogênica, e, uso de uma composição imunogênica |
PE20090146A1 (es) | 2007-04-20 | 2009-03-23 | Glaxosmithkline Biolog Sa | Composicion inmunogenica contra el virus influenza |
US8668904B2 (en) | 2007-12-06 | 2014-03-11 | Glaxosmithkline Biologicals S.A. | Influenza composition |
CA2759397C (en) * | 2009-04-21 | 2019-01-29 | Dow Technology Investments Llc | Improved method of achieving and maintaining a specified alkylene oxide production parameter with a high efficiency catalyst |
-
2008
- 2008-04-15 PE PE2008000650A patent/PE20090146A1/es not_active Application Discontinuation
- 2008-04-15 TW TW097113719A patent/TW200908994A/zh unknown
- 2008-04-15 US US12/103,136 patent/US9452209B2/en active Active
- 2008-04-15 AR ARP080101541A patent/AR066405A1/es not_active Application Discontinuation
- 2008-04-16 CA CA2683075A patent/CA2683075C/en active Active
- 2008-04-16 WO PCT/EP2008/054614 patent/WO2008128939A1/en active Application Filing
- 2008-04-16 AT AT08736288T patent/ATE537841T1/de active
- 2008-04-16 EP EP08736288A patent/EP2136837B1/en active Active
- 2008-04-16 CN CN200880021000A patent/CN101678096A/zh active Pending
- 2008-04-16 CN CN201510848075.XA patent/CN105311629A/zh active Pending
- 2008-04-16 AU AU2008240761A patent/AU2008240761B2/en active Active
- 2008-04-16 EP EP20110194315 patent/EP2455101A3/en not_active Withdrawn
- 2008-04-16 JP JP2010503488A patent/JP2010524883A/ja active Pending
- 2008-04-16 EA EA200901161A patent/EA024250B1/ru not_active IP Right Cessation
- 2008-04-16 ES ES08736288T patent/ES2377761T3/es active Active
- 2008-04-16 KR KR1020097024232A patent/KR101188382B1/ko active IP Right Grant
- 2008-04-16 US US12/596,202 patent/US9597389B2/en active Active
-
2009
- 2009-09-10 IL IL200859A patent/IL200859A/en active IP Right Grant
- 2009-09-28 ZA ZA2009/06753A patent/ZA200906753B/en unknown
- 2009-10-09 DO DO2009000239A patent/DOP2009000239A/es unknown
- 2009-10-28 CO CO09121632A patent/CO6251369A2/es not_active Application Discontinuation
- 2009-11-17 MA MA32351A patent/MA31381B1/fr unknown
- 2009-11-20 CR CR11122A patent/CR11122A/es unknown
-
2017
- 2017-03-01 US US15/446,508 patent/US10016495B2/en active Active
-
2018
- 2018-06-26 US US16/018,292 patent/US10548969B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20090146A1 (es) | Composicion inmunogenica contra el virus influenza | |
HRP20190876T1 (hr) | Novi adjuvantirani pripravci | |
PE20170904A1 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
PE20151588A1 (es) | Vacuna contra el virus del dengue | |
PE20061428A1 (es) | Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl | |
ECSP17057848A (es) | Composiciones farmacéuticas para terapia combinada | |
AR069882A1 (es) | Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e | |
DOP2014000008A (es) | 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk | |
AR056566A1 (es) | Vacunas y procedimientos para tratar la gripe canina | |
BR112012000287B8 (pt) | composição farmacêutica para um inibidor de protease viral de hepatite c | |
CR11455A (es) | Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades | |
BR112015001313A2 (pt) | composições de vacina | |
EA201501033A1 (ru) | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний | |
BR112012004806B8 (pt) | composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso | |
PE20130217A1 (es) | Composiciones farmaceuticas y metodos para su elaboracion | |
BR112014018953A8 (pt) | Derivados de lupano triterpenoide e uso farmacêutico dos mesmos | |
BR112012033767A2 (pt) | processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina. | |
BR112015014174A2 (pt) | composição de vacina para indivíduos virgens | |
ECSP18034035A (es) | Compuestos de criptoficina novedosos y productos conjugados, su preparación y su uso terapéutico | |
AR091006A1 (es) | Formulaciones de testosterona proliposomal | |
JP2013533259A5 (es) | ||
BR112014011345A2 (pt) | partículas tipo vírus da influenza (vlps) compreendendo nicotiana tabacum produzida por hemaglutinina | |
CL2011002302A1 (es) | Uso de una composicion que comprende un monocaprina y un diluyente farmaceuticamente aceptable para el tratamiento de una condicion micotica causada por trichophyton rubrum tal como tinea pedis, tinea crusis, dermatofitosis y onicomicosis. | |
BR112012022939A2 (pt) | composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza | |
BR112013017267A8 (pt) | formulação de lipossomas, suspensão e composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |